Your browser doesn't support javascript.
loading
PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo.
Veiman, Kadi-Liis; Künnapuu, Kadri; Lehto, Tõnis; Kiisholts, Kristina; Pärn, Kalle; Langel, Ülo; Kurrikoff, Kaido.
Afiliación
  • Veiman KL; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia. Electronic address: kadi-liis.veiman@ut.ee.
  • Künnapuu K; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
  • Lehto T; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia; Department of Neurochemistry, The Arrhenius Laboratories for Natural Sciences, Stockholm University, SE-10691 Stockholm, Sweden.
  • Kiisholts K; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
  • Pärn K; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
  • Langel Ü; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia; Department of Neurochemistry, The Arrhenius Laboratories for Natural Sciences, Stockholm University, SE-10691 Stockholm, Sweden.
  • Kurrikoff K; Laboratory of Molecular Biotechnology, Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia.
J Control Release ; 209: 238-47, 2015 Jul 10.
Article en En | MEDLINE | ID: mdl-25935707
ABSTRACT
Gene therapy has great potential to treat a range of different diseases, such as cancer. For that therapeutic gene can be inserted into a plasmid vector and delivered specifically to tumor cells. The most frequently used applications utilize lipoplex and polyplex approaches where DNA is non-covalently condensed into nanoparticles. However, lack of in vivo efficacy is the major concern that hinders translation of such gene therapeutic applications into clinics. In this work we introduce a novel method for in vivo delivery of plasmid DNA (pDNA) and efficient tumor-specific gene induction using intravenous (i.v) administration route. To achieve this, we utilize a cell penetrating peptide (CPP), PepFect14 (PF14), double functionalized with polyethylene glycol (PEG) and a matrix metalloprotease (MMP) substrate. We show that this delivery vector effectively forms nanoparticles, where the condensed CPP and pDNA are shielded by the PEG, in an MMP-reversible manner. Administration of the complexes results in efficient induction of gene expression specifically in tumors, avoiding normal tissues. This strategy is a potent gene delivery platform that can be used for tumor-specific induction of a therapeutic gene.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Polietilenglicoles / Técnicas de Transferencia de Gen / Metaloproteinasa 2 de la Matriz / Lipopéptidos / Péptidos de Penetración Celular / Neoplasias Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2015 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Polietilenglicoles / Técnicas de Transferencia de Gen / Metaloproteinasa 2 de la Matriz / Lipopéptidos / Péptidos de Penetración Celular / Neoplasias Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2015 Tipo del documento: Article